Objective  To evaluate the effectiveness and economic value between hae-mocoagulase agkistrodon and aminocaproic acid and sodium chloride in perioperative inpatients.

Methods  A retrospective database study was conducted in which the clinical efficacy and direct medical cost of perioperative inpatient admitted to tertiary hospitals using haemocoagulase agkistrodon or aminocaproic acid and sodium chloride according to the SuValue® database from January 1st, 2016 to December 31st, 2020. The patients were divided into haemocoagulase agkistrodon group and aminocaproic acid group ac-cording to the different interventions. After matching with propensity score, the effec-tiveness and economic differences between the two groups were compared.

Results  A total of 367 patients were included in each of the two groups. In terms of effectiveness, haemocoagulase agkistrodon significantly reduced estimated total blood loss and length of hospital stay compared with aminocaproic acid (P<0.01). There were no significant dif-ferences in transfusion rate and transfusion volume between the two groups (P>0.05), and the preoperative and postoperative prothrombin time, thrombin time, activated partial thrombin time, fibrinogen level were within the normal range, which did not affect the coagulation function of patients. In terms of economic value, the total cost of hospitali-zation and hemostasis, procoagulant drugs and hemostatic material cost per capita in haemocoagulase agkistrodon group were lower than those in aminocaproic acid group (P<0.05).

Conclusion  The effectiveness and hemostasis economic value of haemocoagulase agkistrodon in perioperative inpatients are superior to that of aminocaproic acid.

1.Ye X, Lafuma A, Torreton E, et al. Incidence and costs of bleeding-related complications in French hospitals following surgery for various diagnoses[J]. BMC Health Serv Res, 2013, 13: 186. DOI: 10.1186/1472-6963-13-186.

2.Fowler AJ, Ahmad T, Phull MK, et al. Meta-analysis of the association between preoperative anaemia and mortality after surgery[J]. Br J Surg, 2015, 102(11): 1314-1324. DOI: 10.1002/bjs.9861.

3.Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review[J]. Lancet, 2013, 382(9896): 984-994. DOI: 10.1016/S0140-6736(12)62197-7.

4.Bosboom JJ, Klanderman RB, Zijp M, et al. Incidence, risk factors, and outcome of transfu-sion-associated circulatory overload in a mixed intensive care unit population: a nested case-control study[J]. Transfusion, 2018, 58(2): 498-506. DOI: 10.1111/trf.14432.

5.Corral M, Ferko N, Hollmann S, et al. Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database[J]. Clinicoecon Out-comes Res, 2015, 7: 409-421. DOI: 10.2147/CEOR.S86369.

6.Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016[J]. Eur J Anaesthesiol, 2017, 34(6): 332-395. DOI: 10.1097/EJA.0000000000000630.

7.Zaidi A, Green L. Physiology of haemostasis[J]. Anaesth Intens Care Med, 2019, 20(3): 152-158. DOI: 10.1016/j.mpaic.2019.01.005.

8.Zhang S, Huang Q, Xu B, et al. Effectiveness and safety of an optimized blood management program in total hip and knee arthroplasty: a large, single-center, retrospective study[J]. Medicine (Baltimore), 2018, 97(1): e94291. DOI: 10.1097/MD.0000000000009429.

9.Gao FQ, Li ZJ, Zhang K, et al. Four methods for calculating blood-loss after total knee arthroplasty[J]. Chin Med J (Engl), 2015, 128(21): 2856-2860. DOI: 10.4103/0366-6999.168041.

10.Yao YT, Yuan X, Fang NX. Hemocoagulase reduces postoperative bleeding and blood transfusion in cardiac surgical patients: a PRISMA-compliant systematic review and meta-analysis[J]. Medicine (Bal-timore), 2019, 98(52): e1853452. DOI: 10.1097/MD.0000000000018534.

11.许静涌, 朱明炜, 江华, 等. 注射用尖吻蝮蛇血凝酶用于手术止血的安全性及有效性的系统评价和Meta分析[J]. 中华普通外科杂志, 2015, 30(4): 308-311. [Xu JY, Zhu MW, Jiang H, et al. Efficacy and safety of hemocoagu-lase agkistrodon injection for intraoperative hemostasis: a systematic review and meta-analysis[J]. Chinese Journal of General Surgery, 2015, 30(4): 308-311.] DOI: 10.3760/cma.j.issn.1007-631X.2015.04.015.

12.郑颖, 沈居仁, 张富强, 等. 尖吻蝮蛇血凝酶N末端序列测定及其止血活性分析[J]. 中国药科大学学报, 2008, 39(4): 365-367. [Zheng Y, Shen JR, Zhang FQ, et al. N-terminal amino acid sequencing of haemocoagulase from agkistrodon acutus venom and analysis of its hemostatic activity[J]. Journal of China Pharmaceu-tical University, 2008, 39(4): 365-367.] DOI: 10.3321/j.issn:1000-5048.2008.04.015.

13.郭娜, 韩晟, 管晓东, 等. 神经外科手术应用尖吻蝮蛇血凝酶的经济性研究[J]. 中国药房, 2016,27(2): 163-165. [Guo N, Han S, Guan XD, et al. Economic evaluation of hemocoagulase agkistrodon used in neurosur-gery operation[J]. China Pharmacy, 2016, 27(2): 163-165.] DOI: 10.6039/j.issn.1001-0408.2016.02.05.

14.赵浩, 李志超, 李海龙, 等. 神经外科手术后应用尖吻蝮蛇血凝酶的临床研究[J]. 中国临床药理学杂志, 2017, 33(13): 1205-1206, 1211. [Zhao H, Li ZC, Li HL, et al. Clinical trial of haemocoagulase agkistrodon application after operation[J]. The Chinese Journal of Clinical Pharmacology, 2017, 33(13): 1205-1206, 1211.] DOI: 10.13699/j.cnki.1001-6821.2017.13.011.

15.陆旭, 杨鑫, 朱明炜, 等. 尖吻蝮蛇血凝酶在乳腺癌手术创面的止血作用[J]. 中国医学科学院学报, 2017, 39(2): 183-187. [Lu X, Yang X, Zhu MW, et al. Hemostatic effect of hemocoagulase agkistrodon on surgical wound in breast cancer surgery[J]. Acta Academiae Medicinae Sinicae, 2017, 39(2): 183-187.] DOI: 10.3881/j.issn.1000-503X.2017.02.004.

16.郝永玉, 张雪松, 杨全中. 注射用尖吻蝮蛇血凝酶在单节段腰椎PLIF手术中应用的安全性和有效性观察[J]. 当代医学, 2020, 26(11): 40-43. [Hao YY, Zhang XS, Yang QZ. The evaluation of the efficacy and safety of hemo-coagulase agkistrodon in patients with lumbar disc herniation undergoing single segment PLIF sur-gery[J]. Contemporary Medicine, 2020, 26(11): 40-43.] DOI: 10.3969/j.issn.1009-4393.2020.11.016.

17.Liu WB, Li GS, Shen P, et al. Comparison between epsilon-aminocaproic acid and tranexamic acid for total hip and knee arthroplasty: a meta-analysis[J]. J Orthop Surg (Hong Kong), 2020, 28(3): 2309499020959158. DOI: 10.1177/2309499020959158.

18.Qin JZ, Wang SJ, Zheng XP, et al. Comparison of hemocoagulase atrox versus tranexamic acid used in primary total knee arthroplasty: a randomized controlled trial[J]. Thromb Res, 2020, 188: 39-43. DOI: 10.1016/j.thromres.2020.02.001.

19.Zhu C, Yang L, Zi H, et al. Using haemocoagulase agkistrodon in patients undergoing transurethral plasmakinetic resection of the prostate: a pilot, real-world, and propensity score-matched study[J]. Biomed Res Int, 2022, 2022: 9200854. DOI: 10.1155/2022/9200854.

20.谢奕丹, 吴晓玲, 关敏婷, 等. 乳腺良性肿块麦默通围手术期应用尖吻蝮蛇血凝酶的药物经济学分析[J]. 医药导报, 2019, 38(4): 499-502. [Xie YD, Wu XL, Guan MT, et al. Pharmacoeconomic analysis of haemocoagulase agkistrodon in perioperative period of breast benign tumor treated with Mammotome system[J]. Herald of Medicine, 2019, 38(4): 499-502.] DOI: 10.3870/j.issn.1004-0781.2019.04.019.

21.Leff J, Rhee A, Nair S, et al. A randomized, double-blinded trial comparing the effectiveness of tranexamic acid and epsilon-aminocaproic acid in reducing bleeding and transfusion in cardiac sur-gery[J]. Ann Card Anaesth, 2019, 22(3): 265-272. DOI: 10.4103/aca.ACA_137_18.

22.崔璨, 高化, 陈文韬, 等. 氨甲环酸与尖吻蝮蛇血凝酶对老年股骨转子间骨折内固定手术止血效果比较[J]. 医药导报, 2021, 40(9): 1228-1231. [Cui C, Gao H, Chen WT, et al. Comparation of tranexamic acid and hemocoagulase agkistrodon on hemo-static effect in internal fixation surgery for senile femoral trochanter fracture[J]. Herald of Medicine, 2021, 40(9): 1228-1231.] DOI: 10.3870/j.issn.1004-0781.2021.09.012

23.Zhong L, Xu Y, Wang Y, et al. Local administration of epsilon-aminocaproic acid reduces post-operative blood loss from surgery for closed, Sanders Ⅲ-Ⅳ calcaneal fractures[J]. Int Orthop, 2022, 46(3): 615-621. DOI: 10.1007/s00264-021-05268-y.

24.Li Z, Sun X, Li W, et al. Tranexamic acid versus epsilon-aminocaproic acid in total knee arthroplasty: a meta-analysis[J]. J Healthc Eng, 2021, 2021: 1758066. DOI: 10.1155/2021/1758066.

25.Oliveira JAA, Brito GCC, Bezerra FMP, et al. The use of antifibrinolytics in hip trauma surgery in a public health system: a prospective study[J]. Acta Ortop Bras, 2021, 29(6): 304-307. DOI: 10.1590/1413-785220212906244502.

26.陈旺, 冯硕, 张羽, 等. 氨甲环酸和ε-氨基己酸减少全膝关节围置换期失血有效和安全性的Meta分析[J]. 中国组织工程研究, 2021, 25(15): 2430-2436. [Chen W, Feng S, Zhang Y, et al. Efficacy and safety of tranexamic acid and epsilon-aminocaproic acid in reducing perioperative blood loss during total knee arthroplasty: a meta-analysis[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(15): 2430-2436.] DOI: 10.3969/j.issn.2095-4344.3821.

27.Klein A, Agarwal S, Cholley B, et al. A survey of patient blood management for patients undergoing cardiac surgery in nine European countries[J]. J Clin Anesth, 2021, 72: 110311. DOI: 10.1016/j.jclinane.2021.110311.

28.姚翀, 郭代红, 王辰允, 等. 32203例注射用尖吻蝮蛇血凝酶相关变态反应自动监测研究[J]. 中国临床药理学杂志, 2020, 36(3): 346-350. [Yao C, Guo DH, Wang YC, et al. Incidence and risk factors of allergic reaction related by haemocoagulase agkistrodon for injection among 32203 patients by automatic surveillance[J]. The Chinese Journal of Clinical Pharmacology,  2020, 36(3): 346-350.] DOI: 10.13699/j.cnki.1001-6821.2020.03.035.

29.罗树军, 魏昌伟, 张菊霞, 等. 尖吻蝮蛇血凝酶不同给药方式对心脏瓣膜置换术患者出血量的影响[J]. 北京医学, 2020, 42(2): 125-128. [Luo SJ, Wei CW, Zhang JX, et al. Effect of different methods of hemocoagulase agkistrodon administration on perioperative blood loss in patients undergoing cardiac valve re-placement[J]. Beijing Medical Journal, 2020, 42(2): 125-128.] DOI: 10.15932/j.0253-9713.2020.02.009.